Patent Application
20090170898
The present invention relates to sulphonamide derivatives, to their use as medicaments (for example in the treatment of an inflammatory disease state), to pharmaceutical compositions comprising them and to processes for preparing them.
Sulphonamide derivatives are disclosed as anti-inflammatories in WO 2004/019935 and WO 2004/050631. Pharmaceutically active sulphonamides are also disclosed in Arch. Pharm. (1980) 313 166-173, J. Med. Chem. (2003) 46 64-73, J. Med. Chem. (1997) 40 996-1004, EP 0031954, EP 1190710 (WO 200124786), U.S. Pat. No. 5,861,401, U.S. Pat. No. 4,948,809, U.S. Pat. No. 3,992,441 to and WO 99/33786.
It is known that certain non-steroidal compounds interact with the glucocorticoid receptor (GR) and, as a result of this interaction, produce a suppression of inflammation (see, for example, U.S. Pat. No. 6,323,199). Such compounds can show a clear dissociation between anti-inflammatory and metabolic actions making them superior to earlier reported steroidal and non-steroidal glucocorticoids. The present invention provides further non-steroidal compounds as modulators (for example agonists, antagonists, partial agonists or partial antagonists) of the glucocorticoid receptor capable of having a dissociation between their anti-inflammatory and metabolic actions.
The present invention provides a compound of formula (I):
wherein:
n is 1 or 2;
A is phenyl, naphthyl, pyridinyl, furyl, thienyl, isoxazolyl, pyrazolyl, benzthienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C1-6 alkyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, nitro, cyano, C(O)2H, C(O)2(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, C(O)(C1-4 alkyl), C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl), NR10R11, phenoxy, phenyl, benzyl, benzyloxy, pyridinyl, pyridinyloxy or pyrazolyl; the substituents phenoxy, phenyl, benzyl, benzyloxy, pyridinyl, pyridinyloxy and pyrazolyl being optionally substituted by halo, C1-6 alkyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, nitro, cyano, C(O)2H, C(O)2(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, C(O)(C1-4 alkyl), benzyloxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl) or NR12R13;
R1 is hydrogen, C1-6 alkyl, phenyl, pyridinylC(O), C3-6 cycloalkyl, (C3-6 cycloalkyl)CH2 or C3-4 alkenyl;
W is cyclohexyl, phenyl, methylenedioxyphenyl, thienyl, pyrazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, benzofuranyl, benzthienyl, indolyl, indolinyl, dihydroindolinyl, indazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, [1,8]-naphthiridinyl, [1,6]-naphthiridinyl, quinolin-2(1H)-onyl, isoquinolin-1(2H)-onyl, phthalazin-1(2H)-onyl, 1H-indazolyl, 1,3-dihydro-2H-indol-2-onyl, isoindolin-1-onyl, 3,4-dihydro-1H-isochromen-1-onyl or 1H-isochromen-1-onyl;
W is optionally substituted by halo, C1-6 alkyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, nitro, cyano, OH, C(O)2H, C(O)2(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, benzyloxy (itself optionally substituted by halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or C1-4 haloalkoxy), imidazolyl, phenyl {itself optionally substituted by halo, C1-6 alkyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, nitro, cyano, OH, C(O)2H, C(O)2(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, benzyloxy, imidazolyl, C(O)(C1-4 alkyl), C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl), NH2, NH(C1-4 alkyl) or N(C1-4 alkyl)2}, pyridyl {itself optionally substituted by halo, C1-6 allyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, nitro, cyano, OH, C(O)2H, C(O)2(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, benzyloxy, imidazolyl, C(O)(C1-4 alkyl), C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl), NH2, NH(C1-4 alkyl) or N(C1-4 alkyl)2}, C(O)(C1-4 alkyl), C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl) or NR14R15;
R10, R11, R12, R13, R14 and R15 are independently, hydrogen, C1-4 alkyl or C3-7 cycloalkyl;
or a pharmaceutically acceptable salt thereof.
Compounds of formula (I) can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.
Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate, p-toluenesulphonate, succinate, glutarate or malonate.
The compounds of formula (I) may exist as solvates (such as hydrates) and the present invention covers all such solvates.
Halogen is, for example, fluorine or chlorine.
Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl.
Haloalkyl (for example fluoroalkyl) comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 halogen (for example fluorine) atoms. In one aspect it is, for example, CHF2, CF3, CH2CF3 or C2F5. In another aspect it is, for example, CHF2, CF3, CH2CF3, C2F5 or CH2Cl. Haloalkoxy (for example fluoroalkoxy) comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 halogen (for example fluorine) atoms. In one aspect it is, for example, OCHF2, OCF3, OCH2CF3 or OC2F5. In another aspect it is, for example, OCHF2, OCF3, OCH2CF3, OC2F5 or OCH2Cl.
Cycloalkyl is for example, cyclopropyl, cyclopentyl or cyclohexyl.
In one particular aspect the present invention provides a compound of formula (I), wherein A is phenyl, pyridyl or pyrazolyl, each being optionally substituted by halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C3-6 cycloalkyl or phenyl (itself optionally substituted by halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or C1-4 haloalkoxy).
In a further aspect the present invention provides a compound of formula (I), wherein A is phenyl optionally substituted by halogen (such as chloro or fluoro), C1-4 alkyl (such as methyl), C1-4 haloalkyl (such as CHF2 or CF3), C1-4 alkoxy (such as methoxy) or C1-4 haloalkoxy (such as OCF3).
In another aspect the present invention provides a compound of formula (I), wherein A is pyridyl optionally substituted by halogen (such as chloro or fluoro), C1-4 alkyl (such as methyl), C1-4 haloalkyl (such as CHF2 or CF3), C1-4 alkoxy (such as methoxy) or C1-4 haloalkoxy (such as OCF3).
In a still further aspect the present invention provides a compound of formula (I), wherein A is pyrazolyl optionally substituted by halogen (such as chloro or fluoro), C1-4 alkyl (such as methyl), C1-4 haloalkyl (such as CHF2 or CF3), C1-4 alkoxy (such as methoxy), C1-4 haloalkoxy (such as OCF3), C3-6 cycloalkyl or phenyl (itself optionally substituted by halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or C1-4 haloalkoxy).
In another aspect the present invention provides a compound of formula (I), wherein n is 1.
In yet another aspect the present invention provides a compound of formula (I), wherein n is 2.
In a further aspect the present invention provides a compound of formula (I), wherein R1 is hydrogen.
In a still further aspect the present invention provides a compound of formula (I) wherein W is phenyl, pyridyl, indolyl (for example indol-4-yl, indol-5-yl, indol-6-yl or indol-7-yl), indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl), quinolinyl (for example quinolin-5-yl) or isoquinolinyl (for example isoquinolin-5-yl).
In another aspect the present invention provides a compound of formula (I) wherein W is indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl or quinolin-5-yl. For example W is indazol-4-yl (such as 1-substituted indazol-4-yl) or quinolin-5-yl.
In a further aspect the present invention provides a compound of formula (I) wherein W is optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy, OCF3, phenyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3), pyridyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3) or C(O)NH2.
In another aspect the present invention provides a compound of formula (I) wherein W is phenyl optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3.
In yet another aspect the present invention provides a compound of formula (I) wherein W is pyridyl optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3.
In a still further aspect the present invention provides a compound of formula (I) wherein W is indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl) and it is optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy, OCF3, phenyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3), pyridyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3) or C(O)NH2.
In another aspect the present invention provides a compound of formula (I) wherein W is indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl) substituted by phenyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3) or pyridyl (itself optionally substituted by halogen, C1-4 alkyl, CF3, C1-4 alkoxy or OCF3).
In yet another aspect the present invention provides a compound of formula (I) wherein W is indazolyl (for example indazol-4-yl) substituted by phenyl (itself optionally substituted by halogen (such as fluoro), C1-4 alkyl (such as methyl), CF3, C1-4 alkoxy (such as methoxy) or OCF3).
In a further aspect the present invention provides a compound of formula (I) wherein W is indazolyl (for example indazol-4-yl) substituted by pyridyl (itself optionally substituted by halogen (such as fluoro), C1-4 alkyl (such as methyl), CF3, C1-4 alkoxy (such as methoxy) or OCF3).
In another aspect the present invention provides a compound of formula (I) wherein n is 1 or 2; R1 is hydrogen; A is phenyl (optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl or OCF3) or pyrazolyl (optionally substituted by halo, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl or phenyl); and, W is quinolinyl (for example quinolin-5-yl) or indazolyl (for example 1-substituted indazol-4-yl) optionally substituted by halophenyl (such as 4-fluorophenyl) or halopyridinyl (such as 2-fluoropyridin-5-yl).
The compounds of formula (I) can be prepared using or adapting methods disclosed in the art, or by using or adapting the method disclosed in the Examples below. Starting materials for the preparative methods are either commercially available or can be prepared by literature methods, adapting literature methods.
For example, a compound of the invention can be prepared by coupling a compound of formula (II):
wherein Y is a leaving group (for example chlorine), with a compound of formula (III):
in a suitable solvent (such as tetrahydrofuran or N,N-dimethylformamide) at a temperature in the range −10° C. to 50° C.
The invention further provides processes for the preparation of the compounds of formula (I).
Because of their ability to bind to the glucocorticoid receptor the compounds of formula (I) are useful as anti-inflammatory agents, and can also display antiallergic, immunosuppressive and anti-proliferative actions. Thus, a compound of formula (I), or a pharmaceutically acceptable salt thereof can be used as a medicament for the treatment or prophylaxis of one or more of the following pathologic conditions (disease states) in a mammal (such as a human):
Without prejudice to the foregoing, the compounds of formula (I) can also be used to treat disorders such as: Conies Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, oesophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cinhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum acne, hirsutism, toxic epiderrmal necrolysis, erythema multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders (such as memory disturbances) mood disorders (such as depression and bipolar disorder), anxiety disorders and personality disorders.
As used herein the term “congestive heart failure” (CHF) or “congestive heart disease” refers to a disease state of the cardiovascular system whereby the heart is unable to efficiently pump an adequate volume of blood to meet the requirements of the body's tissues and organ systems. Typically, CHF is characterized by left ventricular failure (systolic dysfunction) and fluid accumulation in the lungs, with the underlying cause being attributed to one or more heart or cardiovascular disease states including coronary artery disease, myocardial infarction, hypertension, diabetes, valvular heart disease, and cardiomyopathy. The term “diastolic congestive heart failure” refers to a state of CHF characterized by impairment in the ability of the heart to properly relax and fill with blood. Conversely, the term “systolic congestive heart failure” refers to a state of CHF characterized by impairment in the ability of the heart to properly contract and eject blood.
As will be appreciated by one of skill in the art, physiological disorders may present as a “chronic” condition, or an “acute” episode. The term “chronic”, as used herein, means a condition of slow progress and long continuance. As such, a chronic condition is treated when it is diagnosed and treatment continued throughout the course of the disease. Conversely, the term “acute” means an exacerbated event or attack, of short course, followed by a period of remission. Thus, the treatment of physiological disorders contemplates both acute events and chronic conditions. In an acute event, compound is administered at the onset of symptoms and discontinued when the symptoms disappear.
In another aspect the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy (such as a therapy described above).
In yet another aspect the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a glucocorticoid receptor mediated disease state (such as a disease state described above).
In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an inflammatory (such as an arthritic) condition.
In a still further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an asthmatic or dermatological condition.
In another aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of COPD.
The present invention further provides a method of treating a glucocorticoid receptor mediated disease state in a mammal (such as man), which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
In order to use a compound of formula (I), or a pharmaceutically acceptable salt thereof, for the therapeutic treatment of a mammal, said active ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Therefore in another aspect the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, (active ingredient) and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition comprising mixing the active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition can comprise from 0.05 to 99% w (percent by weight), for example from 0.05 to 80% w, such as from 0.10 to 70% w (for example from 0.10 to 50% w), of active ingredient, all percentages by weight being based on total composition.
A pharmaceutical composition of the present invention can be administered in a standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration (such as intravenous or ir intra-articular). Thus, a the compound of formula (I), or a pharmaceutically acceptable salt thereof, may be formulated into the form of, for example, an aerosol, a powder (for example dry or dispersible), a tablet, a capsule, a syrup, a granule, an aqueous or oily solution or suspension, an (lipid) emulsion, a suppository, an ointment, a cream, drops, or a sterile injectable aqueous or oily solution or suspension.
A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule containing between 0.1 mg and 1 g of active ingredient.
In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous, intraarticular or intramuscular injection.
Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β-cyclodextrin may be used to aid formulation.
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. Tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
The invention further relates to combination therapies or compositions wherein a GR agonist of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a GR agonist of formula (I), or a pharmaceutically acceptable salt thereof, is administered concurrently (possibly in the same composition) or sequentially with one or more agents for the treatment of any of the above disease states.
For example, for the treatment of rheumatoid arthritis, osteoarthritis, COPD, asthma or allergic rhinitis a GR agonist of the invention can be combined with one or more agents for the treatment of such a condition. Where such a combination is to be administered by inhalation, then the one or more agents is selected from the list comprising:
In another aspect of the invention where such a combination is for the treatment of COPD, asthma or allergic rhinitis the GR agonist of formula (I), or a pharmaceutically acceptable salt thereof, can be administered by inhalation or by the oral route and this is in combination with a xanthine (such as aminophylline or theophylline) which can be administered by inhalation or by the oral route.
The following Examples illustrate the invention. The following abbreviations are used in the Examples:
NMR spectra were recorded on a 300 MHz Varian Mercury VXR instrument or a 400 MHz Varian UnityINOVA spectrometer or 500 MHz Varian UnityINOVA spectrometer. The central peaks of chloroform-d (δH 7.27 ppm), or DMSO-d6 (δH 2.50 ppm) were used as internal references. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett-Packard 1100 LC-MS system equipped with APCI ionisation chamber or on an Agilent 1100 LC/MSD system with APCI ionisation. Unless stated otherwise, starting materials were commercially available. All solvents and commercial reagents were of laboratory grade and were used as received.
The following methods were used for LC/MS analysis
Method A: Instrument Agilent 1100; Column C18 Waters Symmetry 2.1×30 mm 3.5 μm; Flow rate 0.7 ml/min; Mass APCI; UV-absorption was measured at 254 nm; Solvent A: water+0.1% TFA; Solvent B: acetonitrile+0.1% TFA; Gradient 5-95%/B 8 min, 95% B 2 min.
Method B: Instrument Agilent 1100; Column Kromasil C18 3×100 mm 5 μm; Flow rate 1.0 ml/min; UV-absorption was measured at 254 nm; Solvent A: water+0.1% TFA; Solvent B: acetonitrile+0.1% TFA; Gradient 10-100% B 20 min, 100% B 1 min.
BINAP (0.032 mmole, 22 mg) and Pd2(dba)3 (0.011 mmole, 10 mg) were stirred in toluene(1 mL, 4 Å) under argon for 10 mins. (3S)-(−)-3-(tert-butoxycarbonylamino)-pyrrolidine (0.6 mmole, 111 mg) and 5-bromoquinoline (0.51 mmole, 105 mg) and then sodium tert-butoxide (0.71 mmole, 68 mg) were added. The reaction mixture was degassed and the reaction tube was filled with argon before it was heated in a microwave reactor (200W, 25 mins., 90° C.). Ethyl acetate was added and the mixture was filtered and evaporated. The product was purified on silica gel column chromatography (isohexane-ethyl acetate) to yield a yellow gum (103 mg).
APCI-MS m/z: 314.2 [MH+].
1H NMR (399.99 MHz, CDCl3) δ 8.88 (s, 1H), 8.50 (d, J=8.7 Hz, 1H), 7.72 (d, J=8.3 Hz, 1H), 7.59 (t, J=8.0 Hz, 1H), 7.35 (dd, J=8.6, 4.2 Hz, 1H), 6.97 (d, J=7.6 Hz, 1H), 4.91 (s, 1H), 4.41 (s, 1H), 3.64-3.53 (m, 2H), 3.31-3.20 (m, 2H), 2.47-2.36 (m, 1H), 1.98-1.87 (m, 1H), 1.48 (s, 9H)
tert-Butyl (3S)-1-quinolin-5-ylpyrrolidin-3-ylcarbamate (103 mg) was stirred in TFA (5 ml) for 15 mins. at RT. The solvent was evaporated. 2M sodium hydroxide solution was added to the residue and the product was extracted into dichloromethane (3×20 ml). The organic layer was dried and evaporated to yield a yellow gum (60 mg).
APCI-MS m/z: 214.1 [MH+].
(3S)-1-Quinolin-5-ylpyrrolidin-3-amine (60 mg, 0.28 mmole) and 2-mesitylenesulfonyl chloride (74 mg, 0.338 mmole) were dissolved in pyridine (2 mL) and stirred at room temperature overnight. The mixture was evaporated, dissolved in ethyl acetate (60 ml) and washed with water (3×10 ml) and brine (110 ml). The organic layer was dried, concentrated and purified by silica gel column chromatography (isohexane-ethyl acetate), then by RPHPLC-C18, then by silica gel column chromatography (2% ammonia/methanol/dichloromethane) to yield a pale yellow solid (25 mg).
APCI-MS m/z: 396.0 [MH+].
1H NMR (299.944 MHz, CDCl3) δ 8.88 (dd, J=4.1, 1.7 Hz, 1H), 8.37 (ddd, J=8.6, 1.7, 0.9 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.56 (t, J=8.1 Hz, 1H), 7.33 (dd, J=8.6, 4.2 Hz, 1H), 6.93 (s, 2H), 6.90 (dd, J=7.7, 0.9 Hz, 1H), 4.90 (d, J=8.1 Hz, 1H), 4.10-3.98 (m, 1H), 3.56-3.46 (m, 1H), 3.34 (dd, J=10.1, 5.5 Hz, 1H), 3.24-3.12 (m, 2H), 2.66 (s, 6H), 2.38-2.24 (m, 1H), 2.29 (s, 3H), 2.00-1.87 (m, 1H)
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.94 (d, J=3.8 Hz, 1H), 8.84 (d, J=8.6 Hz, 1H), 8.62 (d, J=5.3 Hz, 1H), 7.70 (t, J=8.1 Hz, 1H), 7.59 (dd, J=8.6, 4.9 Hz, 1H), 7.54 (s, 2H), 7.42 (d, J=8.4 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 4.05-3.98 (m, 1H), 3.68 (dd, J=10.4, 5.3 Hz, 1H), 3.59-3.50 (m, 1H), 3.50-3.33 (m, 2H obscured), 2.16-2.07 (m, 1H), 2.06-1.98 (m, 1H)
MS (APCI) e/z: 456.20 (MH)+
4-Bromo-1H-indazole (600 mg) was dissolved in CH2Cl2 (28 mL). 2-Fluoropyridine-5-boronic acid (650 mg), anhydrous cupric acetate (620 mg) and pyridine (370 μL) were added followed by 4 Å molecular sieves (600 mg). The reaction mixture was stirred for 72 hours and then filtered through celite with methanol. The filtrate was evaporated and purified by silica gel column chromatography (isohexane-diethyl ether) to yield a pale orange solid (310 mg).
1H NMR (399.99 MHz, CDCl3) δ 8.62 (s, 1H), 8.28 (s, 1H), 8.20-8.14 (m, 1H), 7.61 (d, J=8.3 Hz, 1H), 7.45 (d, J=7.1 Hz, 1H), 7.35 (dt, J=0.2, 7.8 Hz, 1H), 7.16 (dd, J=8.8, 3.3 Hz, 1H)
MS (APCI) e/z: 292/293.9 (NH)+
Was prepared analogous to Example 1a) but with corresponding starting material.
MS (APCI) e/z: 398.2 (MH)+
1H-NMR (399.988 MHz, CDCl3): δ 8.63 (s, 1H), 8.33 (s, 1H), 8.18-8.13 (m, 1H), 7.31 (t, J=8.1 Hz, 1H), 7.12 (dd, J=8.7, 3.2 Hz, 1H), 6.95 (d, J=8.1 Hz, 1H), 6.19 (d, J=7.8 Hz, 1H), 4.78 (s, 1H), 4.46 (s, 1H), 3.95 (dd, J=9.7, 5.8 Hz, 1H), 3.88-3.79 (m, 1H), 3.79-3.71 (m, 1H), 3.56-3.50 (m, 1H), 2.43-2.32 (m, 1H), 2.13-2.02 (m, 1H), 1.48 (s, 9H)
Was prepared analogous to Example 1b) but with corresponding starting material.
MS (APCI) e/z: 298.1 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting materials.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.60-8.56 (m, 2H), 8.31 (ddd, J=9.1, 6.7, 2.5 Hz, 1H), 8.24 (s, 1H), 7.57 (s, 2H), 7.37 (dd, J=8.8, 3.1 Hz, 1H), 7.19 (t, J=8.0 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.04 (d, J=7.7 Hz, 1H), 4.05 (q, J=4.9 Hz, 1H), 3.70-3.60 (m, 2H), 3.50-3.25 (m, 2H obscured), 2.17-2.00 (m, 2H)
MS (APCI) e/z: 540.20 (MH)+
Was prepared analogous to Example 3a) and 1a) but with corresponding starting material.
MS (APCI) e/z: 397.2 (MH)+
1H-NMR (299.944 MHz, CDCl3): δ 8.29 (d, J=0.7 Hz, 1H), 7.71-7.63 (m, 2H), 7.30-7.17 (m, 3H), 6.95 (d, J=8.4 Hz, 1H), 6.16 (d, J=7.7 Hz, 1H), 4.78 (s, 1H), 4.45 (s, 1H), 3.98-3.89 (m, 1H), 3.89-3.69 (m, 2H), 3.53 (dd, J=9.9, 3.9 Hz, 1H), 2.43-2.29 (m, 1H), 2.13-2.00 (m, 1H), 1.48 (s, 9H)
Was prepared analogous to Example 1b) but with corresponding starting material.
MS (APCI) e/z: 297.1 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.60 (d, J=5.8 Hz, 1H), 8.16 (s, 1H), 7.69 (dd, J=9.0, 4.8 Hz, 2H), 7.59 (s, 2H), 7.36 (t, J=8.8 Hz, 2H), 7.15 (t, J=8.1 Hz, 1H), 6.86 (d, J=8.4 Hz, 1H), 5.99 (d, J=7.7 Hz, 1H), 4.07-4.01 (m, 1H), 3.69-3.60 (m, 2H), 2.77-2.43 (m, 2H obscured), 2.15-1.99 (m, 2H)
MS (APCI) e/z: 539.15 (MH)+
Was prepared analogous to Example 3) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.57 (d, J=2.0 Hz, 1H), 8.33-8.27 (m, 2H), 8.22 (s, 1H), 7.43 (d, J=2.2 Hz, 1H), 7.39-7.33 (m, 2H), 7.19 (t, J=8.1 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.04 (d, J=7.7 Hz, 1H), 4.04-3.96 (m, 1H), 3.67-3.58 (m, 2H), 3.5-3.3 (m, 2H obscured), 2.55-2.45 (s, 3H obscured), 2.10-1.92 (m, 2H)
MS (APCI) e/z: 520.25 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.93 (d, J=4.0 Hz, 1H), 8.81 (d, J=8.6 Hz, 1H), 8.32 (d, J=6.2 Hz, 1H), 7.70 (t, J=8.2 Hz, 1H), 7.57 (dd, J=8.6, 4.9 Hz, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.38 (s, 1H), 7.29 (s, 1H), 6.86 (d, J=8.0 Hz, 1H), 3.97 (q, J=4.9 Hz, 1H), 3.62-3.56 (m, 1H), 3.5-3.4 (m, 1H obscured), 2.6-2.4 (m, 2H and s, 3H obscured), 2.15-1.91 (m, 2H)
MS (APCI) e/z: 436.25 (MH)+
N-{(3S)-1-[1-(6-Fluoropyridin-3-yl)-1H-indazol-4-yl]pyrrolidin-3-yl}-2,4,6-trimethylbenzenesulfonamide
Was prepared analogous to Example 3 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.56 (d, J=2.7 Hz, 1H), 8.31-8.27 (m, 1H), 8.12 (s, 1H), 7.87 (d, J=6.9 Hz, 1H), 7.37 (dd, J=8.9, 2.7 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 6.99 (s, 2H), 6.91 (d, J=8.9 Hz, 1H), 6.03 (d, J=7.9 Hz, 1H), 3.86 (q, J=8.8 Hz, 1H), 3.60-3.55 (m, 1H), 3.53-3.42 (m, 1H), 2.55-2.45 (s, 6H obscured), 2.22 (s, 3H), 2.06-1.97 (m, 2H), 1.94-1.84 (m, 2H)
MS (APCI) e/z: 480.35 (MH)+
Was prepared analogous to Example 3 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.03 (s, 1H), 7.86 (d, J=7.1 Hz, 1H), 7.70-7.64 (m, 2H), 7.36 (t, J=14.9 Hz, 2H), 7.15 (t, J=8.0 Hz, 1H), 6.99 (s, 2H), 6.86 (d, J=8.2 Hz, 1H), 5.99 (d, J=8.0 Hz, 1H), 3.85 (q, J1=6.1 Hz, 1H), 3.56 (q, J=7.4 Hz, 1H), 3.5-3.3 (m, 1H obscured), 2.55-2.45 (m, 2H and s, 6H obscured), 2.22 (s, 3H), 2.02 (sextet, J=6.4 Hz, 1H), 1.93-1.83 (m, 1H)
MS (APCI) e/z: 479.30 (MH)+
Was prepared analogous to Example 3 but with corresponding starting materials.
2,4-Pentadion (5.5 g, 55 mmol), cyclopentylhydrazinhydrochloride (6.83 g, 50 mmol) and DIEA (9.58 ml, 55 mmol) were dissolved in ethanol and was refuxed for 48 hours. 0.5 M Citric acid solution and ethyl acetate were added and the organic phase was washed with NaHCO3 and Brine. The organic layer was dried and evaporated to yield a colourless oil (6.70 g). The oil was dissolved in CHCl3 (25 ml) chilled with ice and added to chloridosulfuric acid (30 ml). The mixture was stirred at 0° C. for one hour and was then refuxed for two hours. The mixture was allowed to reach room temperature, thionyl chloride (10 ml) was added and the mixture was refluxed for two hours. The solvent was evaporated and the residue was very slowly poured on ice/Na2CO3. Water was added to the chilled neutral solution and the resulting solid (11.4 g) was collected and dried.
MS (APCI) e/z: 263.75 (MH)+
Was prepared analogous to Example 3 but with corresponding starting materials
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.73-7.62 (m, 3H), 7.40-7.33 (m, 2H), 7.17 (t, J=8.1 Hz, 1H), 6.87 (d, J=8.2 Hz, 1H), 6.01 (d, J=8.0 Hz, 1H), 4.63 (quintet, J=12.7 Hz, 1H), 3.80 (sextet, J=7.4 Hz, 1H), 3.62 (q, J=10.4 Hz, 1H), 3.57-3.48 (m, 1H), 2.76-2.56 (m, 1H), 2.55-2.45 (m, 1H and s, 3H obscured), 2.26 (s, 3H), 2.15-2.03 (m, 1H), 2.00-1.87 (m, 3H), 1.87-1.70 (m, 4H), 1.60-1.50 (m, 2H)
MS (APCI) e/z: 523.40 NH)+
Was prepared analogous to Example 9 but with corresponding starting material.
Purified by RPHPLC-C18
1H NMR (499.881 MHz, DMSO-d6) δ 8.93 (d, J=3.8 Hz, 1H), 8.86 (d, J=8.0 Hz, 1H), 7.74-7.67 (m, 2H), 7.59 (dd, J=8.6, 4.6 Hz, 1H), 7.45 (d, J=8.2 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 4.60 (quintet, J=10.0 Hz, 1H), 3.79-3.71 (m, 1H), 3.56-3.21 (m, 2H obscured), 2.75-2.35 (m, 2H obscured), 2.38 (s, 3H), 2.21 (s, 3H), 2.11-2.03 (m, 1H), 1.94-1.81 (m, 3H), 1.79-1.67 (m, 4H), 1.59-1.48 (m, 2H)
MS (APCI) e/z: 440.30 (MH)+
Was prepared analogous to Example 9) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.25 (s, 1H), 8.11 (d, J=6.6 Hz, 1H), 7.79 (s, 1H), 7.68 (dd, J=9.0, 5.0 Hz, 2H), 7.36 (t, J=8.5 Hz, 2H), 7.18 (t, J=8.1 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.04 (d, J=7.7 Hz, 1H), 3.87 (q, J=5.7 Hz, 1H), 3.68-3.61 (m, 2H), 3.58-3.49 (m, 1H), 2.77-2.67 (m, 1H), 2.55-2.45 (s, 3H obscured), 2.32 (s, 3H), 2.15-2.05 (m, 1H), 1.97-1.86 (m, 1H).
MS (APCI) e/z: 505.25 (MH)+
N-{(3S)-1-[1-(4-Fluorophenyl)-1H-indazol-4-yl]pyrrolidin-3-yl}-2,4-dimethylbenzenesulfonamide
Was prepared analogous to Example 3 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.98 (d, J=6.2 Hz, 1H), 7.73 (d, J=13.2 Hz, 1H), 7.68-7.65 (m, 2H), 7.36 (t, J=15.8 Hz, 2H), 7.19-7.11 (m, 3H), 6.86 (d, J=19.5 Hz, 1H), 6.00 (d, J=7.7 Hz, 1H), 3.84-3.75 (m, 1H), 3.55-3.25 (m, 2H obscured), 2.75-2.4 (m, 2H, and s, 3H obscured), 2.28 (s, 3H), 2.08-1.96 (m, 1H), 1.95-1.82 (m., 1H)
MS (APCI) e/z: 465.35 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.87 (d, J=4.7 Hz, 1H), 8.69 (d, J=8.3 Hz, 1H), 7.97 (d, J=6.5 Hz, 1H), 7.65 (t, J=12.1 Hz, 2H), 7.53-7.49 (m, 1H), 7.43 (d, J=9.2 Hz, 1H), 7.03 (d, J=10.0 Hz, 2H), 6.85 (d, J=8.2 Hz, 1H), 3.80-3.70 (m, 1H), 3.24-3.17 (m, 2H), 2.78-2.66 (m, 1H), 2.55-2.45 (m, 1H and s, 3H obscured), 2.22 (s, 3H), 2.07-1.97 (m, 1H), 1.91-1.82 (m, 1H)
MS (APCI) e/z: 382.25 (MH)+
Was prepared analogous to Example 9 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.32-8.25 (m, 2H), 7.71 (d, J=6.9 Hz, 1H), 7.37 (dd, J=8.4, 3.0 Hz, 1H), 7.21 (t, J=8.0 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.05 (d, J=8.1 Hz, 1H), 4.64 (quintet, J=7.3 Hz, 1H), 3.81 (sextet, J=7.3 Hz, 1H), 3.67-3.60 (m, 1H), 3.58-3.49 (m, 1H), 2.55-2.45 (s, 3H obscured), 2.25 (s, 3H), 2.13-2.03 (m, 2H), 2.01-1.89 (m, 4H), 1.88-1.70 (m, 4H), 1.61-1.51 (m, 2H)
MS (APCI) e/z: 524.30 (MH)+
Was prepared analogous to Example 9 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.25 (s, 1H), 8.00 (d, J=12.5 Hz, 1H), 7.95 (s, 1H), 7.67 (dd, J=9.1, 5.1 Hz, 2H), 7.50 (dd, J=15.7, 6.6 Hz, 5H), 7.37 (t, J=8.8 Hz, 2H), 7.18 (t, J=7.9 Hz, 1H), 6.88 (d, J=7.7 Hz, 1H), 6.06 (d, J=8.0 Hz, 1H), 3.97-3.90 (m, 1H), 3.72-3.64 (m, 2H), 3.58-3.50 (m, 1H), 2.77-2.69 (m, 1H), 2.55-2.45 (s, 3H obscured), 2.21-2.09 (m, 1H), 2.04-1.93 (m, 1H)
MS (APCI) e/z: 517.25 (MH)+
Was prepared analogous to Example 9 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.86 (d, J=5.0 Hz, 1H), 8.76 (d, J=8.1 Hz, 1H), 8.00 (d, J=6.5 Hz, 1H), 7.89 (s, 1H), 7.65 (t, J=8.3 Hz, 1H), 7.54-7.40 (m, 7H), 6.91 (d, J=8.0 Hz, 1H), 3.91-3.84 (m, 1H), 3.34-3.27 (m, 1H), 2.77-2.66 (m, 1H), 2.40 (s, 3H obscured), 2.20-2.09 (m, 2H), 1.96-1.85 (m, 2H).
MS (APCI) e/z: 434.30 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.92 (d, J=4.8 Hz, 1H), 8.82 (d, J=8.5 Hz, 1H), 8.47 (d, J=6.4 Hz, 1H), 7.82 (d, J=8.4 Hz, 1H), 7.72-7.67 (m, 3H), 7.58 (dd, J=8.8, 4.9 Hz, 1H), 7.46 (d, J=8.2 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H), 3.95 (sextet, J=6.9 Hz, 1H), 3.55-3.35 (m, 1H obscured), 3.30 (dd, J=10.0, 4.4 Hz, 1H), 2.8-2.35 (m, 2H obscured), 2.15-2.06 (m, 1H), 1.95-1.87 (m, 1H)
MS (APCI) e/z: 516.20 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.93 (d, J=3.5 Hz, 1H), 8.87 (d, J=8.4 Hz, 1H), 8.13 (d, J=6.6 Hz, 1H), 7.75 (t, J=57.1 Hz, 1H), 7.70 (t, J=8.2 Hz, 1H), 7.59 (dd, J=8.6, 4.9 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 6.92 (d, J=8.0 Hz, 1H), 3.83 (q, J=5.8 Hz, 1H), 3.58-3.50 (m, 1H), 3.55-3.45 (m, 1H obscured), 2.77-2.4 (m, 2H, and s, 3H obscured), 2.27 (s, 3H), 2.15-2.05 (m, 1H), 1.91-1.81 (m, 1H)
MS (APCI) e/z: 422.30 (MH)+
Was prepared analogous to Example 3 but with corresponding starting material.
Purified by RPHPLC-C18.
1H NMR (499.881 MHz, DMSO-d6) δ 8.12 (s, 1H), 8.02 (d, J=7.8 Hz, 1H), 7.69-7.64 (m, 3H), 7.36 (t, J=8.8 Hz, 2H), 7.27 (d, J=8.8 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 7.16 (t, J=8.3 Hz, 1H), 6.86 (d, J=8.1 Hz, 1H), 5.99 (d, J=7.8 Hz, 1H), 3.88-3.80 (m, 1H), 3.65-3.57 (m, 1H), 3.50-3.30 (m, 1H obscured), 2.80-2.30 (m, 2H obscured), 2.26 (s, 3H), 2.09-1.97 (m, 1H), 1.96-1.84 (m, 1H)
MS (APCI) e/z: 465.20 (MH)+
Was prepared analogous to Example 1c) but with corresponding starting material.
MS (APCI) e/z: 283.10 (M-BOC)+
1H-NMR (399.99 MHz, CDCl3): δ 6.97 (s, 2H), 4.67 (s, 1H), 3.60-2.97 (m, 5H), 2.66 (s, 6H), 2.31 (s, 3H), 1.79-1.38 (m, 4H), 1.44 (s, 9H)
Was prepared analogous to Example 1b) but with corresponding starting material.
MS (APCI) e/z: 283.10 (MH)+
Was prepared analogous to Example 1a) but with corresponding starting material. Purified by silica gel column chromatography (isohexane-ethyl acetate), then by RPHPLC-C18.
MS (APCI) e/z: 493.20 (MH)+
1H-NMR (399.99 MHz, DMSO-d6): δ 7.88-7.83 (m, 2H), 7.74 (dd, J=9.0, 4.8 Hz, 2H), 7.43 (t, J=8.8 Hz, 2H), 7.30-7.19 (m, 2H), 7.04 (s, 2H), 6.43 (d, J=7.1 Hz, 1H), 3.47 (t, J=11.0 Hz, 2H), 3.29-3.17 (m, 1H), 2.78 (t, J=10.5 Hz, 1H), 2.70-2.61 (m, 1H), 2.60 (s, 6H), 2.27 (s, 3H), 1.85-1.71 (m, 2H), 1.66-1.52 (m, 1H), 1.48-1.34 (m, 1H)
The assay is based on a commercial kit from Panvera/Invitrogen (Part number P2893). The assay technology is fluorescence polarization. The kit utilises recombinant human GR (Panvera, Part number P2812), a Fluoromone™ labelled tracer (GS Red, Panvera, Part number P2894) and a Stabilizing Peptide 10× (Panvera, Part number P2815). The GR and Stabilizing Peptide reagents are stored at −70° C. while the GS Red is stored at −20° C. Also included in the kit are 1M DTT (Panvera, Part number P2325, stored at −20° C.) and GR Screening buffer 10× (Panvera, Part number P2814, stored at −70° C. initially but once thawed stored at room temperature). Avoid repeated freeze/thaws for all reagents. The GR Screening buffer 10× comprises 100 mM potassium phosphate, 200 mM sodium molybdate, 1 mM EDTA and 20% DMSO.
Test compounds (1 μL) and controls (1 μL) in 100% DMSO were added to black polystyrene 384-well plates (Greiner low volume black flat-bottom, part number 784076). 0% control was 100% DMSO and 100% control was 10 μM Dexamethasone. Background solution (8 μL; assay buffer 10×, Stabilizing Peptide, DTT and ice cold MQ water) was added to the background wells. GS Red solution (7 μL; assay buffer 10×, Stabilizing Peptide, DTT, GS Red and ice cold water) was added to all wells except background wells. GR solution (7 μL; assay buffer 10×, Stabilizing Peptide, DTT, GR and ice cold water) was added to all wells. The plate was sealed and incubated in a dark at room temperature for 2 hours. The plate was read in an Analyst plate reader (LJL Biosystems/Molecular Devices Corporation) or other similar plate reader capable of recording fluorescence polarization (excitation wavelength 530 nm, emission wavelength 590 nM and a dichroic mirror at 561 nm). The IC50 values were calculated using XLfit model 205 and are shown, for certain compounds of the invention, in the table below.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SE07/00304 | 3/29/2007 | WO | 00 | 9/29/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60788274 | Mar 2006 | US |
